Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Filaggrin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Filaggrin. Displaying page 1 of 1.
    EudraCT Number: 2007-003106-99 Sponsor Protocol Number: ELBE II-2007 Start Date*: 2007-10-04
    Sponsor Name:University of Kiel, Department of Dermatology
    Full Title: Pimecrolimus and Epidermal Barrier Function: Role for pimecrolimus in restoring skin barrier function and normalizing epidermal lipid content and differentiation in atopic epidermis: a randomized, ...
    Medical condition: Investigative study of pathogenesis/treatment of calcineurin inhibitor vs. corticosteroid confirmatory study to prior study: Pimecrolimus and Epidermal Barrier Function, Protocol No. ELBE-2005, Eud...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004370-96 Sponsor Protocol Number: LG-TCS-AD Start Date*: 2019-02-15
    Sponsor Name:Jacob Pontoppidan Thyssen
    Full Title: The effects of topical corticosteroid use on insulin sensitivity and bone turnover
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-003050-24 Sponsor Protocol Number: B7931022 Start Date*: 2019-08-02
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06700841 CREAM APPLIED ONCE OR T...
    Medical condition: Atopic Dermatitis (AD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) HU (Completed) BG (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-021284-33 Sponsor Protocol Number: protocoltwo17.12.09. Start Date*: 2010-10-07
    Sponsor Name:Research and Development Department, John Radcliffe Hospital
    Full Title: Proof of concept study of combined allergen immunotherapy and antibiotics for the treatment of chronic atopic eczema
    Medical condition: Severe chronic atopic eczema
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012435 Dermatitis and eczema HLT
    12.1 10001712 Allergic eczema LLT
    12.1 10003641 Atopic eczema LLT
    12.1 10012454 Dermatitis eczematoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002643-23 Sponsor Protocol Number: STH19966 Start Date*: 2020-03-23
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: Validation of a novel composite of skin biomarkers as a primary outcome measure for evaluating the safety of treatments for atopic dermatitis: a randomized controlled trial (phase 2) comparing the ...
    Medical condition: atopic eczema (synonym atopic dermatitis) and the adverse treatment side effect epidermal atrophy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10003641 Atopic eczema LLT
    21.0 10040785 - Skin and subcutaneous tissue disorders 10040799 Skin atrophy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-004741-27 Sponsor Protocol Number: DM14/11351 Start Date*: 2015-02-18
    Sponsor Name:University of Leeds
    Full Title: Comparison of Alitretinoin with PUVA as the first line treatment in patients with severe chronic hand eczema
    Medical condition: Severe chronic hand eczema
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10066558 Chronic eczema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-003162-42 Sponsor Protocol Number: M/37779/21 Start Date*: 2005-10-21
    Sponsor Name:Almirall Prodesfarma S.A.
    Full Title: A double-blind, randomized, parallel, multicenter, vehicle-controlled, left/right paired comparison to study the efficacy, safety and tolerability of 1% LAS 37779 cream administered once and twice ...
    Medical condition: patients with mild to moderate chronic plaque psoriasis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004542-28 Sponsor Protocol Number: NL59862.091.16 Start Date*: 2017-09-14
    Sponsor Name:Radboud University Medical Center
    Full Title: A randomized controlled pilot study comparing the efficacy of topical coal tar to topical corticosteroids in children aged 1 to < 16 years with moderate-severe atopic dermatitis.
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004687-19 Sponsor Protocol Number: NL59928.091.16 Start Date*: 2018-04-23
    Sponsor Name:Radboud University Medical Center
    Full Title: A randomized controlled trial evaluating the additional effect of topical coal tar to a topical corticosteroid regimen in patients aged >16 years of age with moderate-severe atopic dermatitis.
    Medical condition: Atopic Dermatitis (AD)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-000598-22 Sponsor Protocol Number: TRA-WEI-0015-I Start Date*: 2020-07-13
    Sponsor Name:University Hospital Schleswig Holstein, Represented by the Board of Directors which is represented by the chairman
    Full Title: Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki)
    Medical condition: Patients with moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002573-21 Sponsor Protocol Number: B7451029 Start Date*: 2019-02-11
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 AND DUPILUMAB IN COMPARISON WITH PLACEB...
    Medical condition: Moderate to severe atopic dermatitis (AD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BG (Completed) CZ (Completed) LV (Completed) FR (Completed) HU (Completed) AT (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002550-32 Sponsor Protocol Number: VIPES Start Date*: 2012-12-21
    Sponsor Name:DBV Technologies SA
    Full Title: A double-blind, placebo-controlled, randomized trial to study the Viaskin® Peanut’s Efficacy and Safety for treating peanut allergy in children and adults.
    Medical condition: Treatment of peanut allergy in adults and children age 6 years and older with documented hypersensitivity to peanut. The induction of clinical desensitization to peanut in patients allergic to pean...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004870 10034202 Peanut allergy LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed) PL (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003804-37 Sponsor Protocol Number: B7451036 Start Date*: 2019-05-14
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTI CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF 04965842 CO ADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESC...
    Medical condition: Moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) LV (Completed) PL (Completed) GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001997-52 Sponsor Protocol Number: 20170755 Start Date*: 2018-12-28
    Sponsor Name:Amgen Inc
    Full Title: A Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tezepelumab Alone or Combined with Topical Corticosteroids in Moderate-to-Severe Atopic Dermatitis.
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) GB (GB - no longer in EU/EEA) LV (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) PL (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 16:16:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA